GlaxoSmithKline, Novartis deal

Novartis purchased rights to ofatumumab in non-oncology indications from GlaxoSmithKline and now has full rights to the compound. Novartis markets ofatumumab as Arzerra to treat chronic lymphocytic leukemia (CLL). The pharma purchased rights to ofatumumab in oncology indications from GSK in an asset swap that closed in March. Next year, Novartis plans to move the human mAb against CD20 into a Phase III trial to treat relapsing-remitting multiple sclerosis (RRMS). ...